2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma

This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan). This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.PMID:34482771 | DOI:10.1080/14737140.2021.1976147
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Source Type: research